Exelixis Inc | search
Click here to view Exelixis Inc news from 60+ newspapers.
Bookmark or Share- Exelixis - WikipediaExelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
- Shaping the Future of Oncology for Patients l ExelixisExelixis is an oncology-focused biotech company innovating cancer treatments for life. Find out how we're dedicated to giving more patients hope for the future.
- Building a Legacy of Oncology Excellence l ExelixisA look ahead. The future of cancer care will be determined by the role of new chemical entities and combination regimens. Exelixis’ medicines are advancing the company’s mission to help cancer patients recover stronger and live longer.
- Investors and News | ExelixisLatest news. 04/16/24. Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024. 02/27/24. Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March. 02/06/24. Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update. 02/01/24.
- Exelixis Inc (EXEL) Q1 2024 Earnings: Mixed Results Amidst ...On April 30, 2024, Exelixis Inc ( NASDAQ:EXEL) released its first-quarter financial results for 2024, revealing a mixed financial performance with total revenues of $425 million, which fell short ...
More
